Fidelity Advisor Biotechnology A (FBTAX) Fund Overview
Fidelity Advisor Biotechnology A (FBTAX) — price $46.03 (+0.07%), as of the Nov 19, 2026 trading session.
Educational signal · not a buy or sell recommendation · How to read this
Fidelity Advisor Biotechnology A · FBTAX
Fidelity Advisor Biotechnology Fund Class A (FBTAX) is a non-diversified fund focused on capital appreciation through investments in biotechnology companies. The fund primarily invests in common stocks of companies engaged in the research, development, and distribution of biotechnological products and services.
Price as of Nov 19, 2026
Key Statistics
Not scored: this is a debt/preferred or other non-common instrument, or its reported market value does not match its share basis.
Price & valuation
| Measure | Value |
|---|---|
| Latest provided price | $46.03 |
| Change on the day | +0.07% |
| Price / earnings (trailing) | 12.75 |
Price & events
What is Fidelity Advisor Biotechnology A (FBTAX), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Fidelity Advisor Biotechnology A (FBTAX) is the company analyzed here. In Q4 FY2023 it reported revenue of $149M and net income of $22M.
What do the latest results show for Fidelity Advisor Biotechnology A (FBTAX)?
Short answer · as of
The most recent reported quarter, Q4 FY2023, carried revenue of $149M.
Quarterly income statement — 1 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 FY2023 | $149M | $22M | $1.57 (diluted) |
What are the financial strengths and risks for Fidelity Advisor Biotechnology A (FBTAX)?
Short answer · as of
The distress and quality screens read Altman Z 13.16 · Piotroski F 8. Trailing ratios: ROE 42.5% · ROA 19.4% · current ratio 1.53 · free-cash-flow yield 1.9%.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held FBTAX in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported FBTAX in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Fidelity Advisor Biotechnology A Stock: Key Questions Answered
These answers are editorial: 1 of these 1 answer is drawn from the FBTAX research dossier (written Mar 16, 2026 by gemini-2.0-flash). Figures in this section are not part of the source register.
How does Fidelity Advisor Biotechnology Fund Class A generate revenue?
Fidelity Advisor Biotechnology Fund Class A (FBTAX) generates revenue primarily through management fees, which are charged as a percentage of the fund's assets under management (AUM). These fees compensate Fidelity for its expertise in selecting and managing the fund's investments.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 9 figures on this page — 7 from Financial Modeling Prep (FMP) and 2 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com